Pharmaceutical Technology

MAY 2, 2023

IO agents include the classes of immune checkpoint modulators, cell therapies, bispecific antibodies, oncolytic viruses, therapeutic vaccines, and cytokines. IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

pharmaphorum

JANUARY 5, 2022

Teliso-V is currently in a 233-patient phase 2 study (LUMINOSITY) involving subjects with c-Met-positive, non-squamous NSCLC as a second- or third-line treatment after chemotherapy, immunotherapy with checkpoint inhibitors or drugs targeted at specific mutations. Preliminary results from that study showed a 53.8%

Antibody 111

Antibody Drugs Protein Gene 111

Roots Analysis

MARCH 1, 2024

Overt security features are basically security checkpoints that are meant for end users. The examples of unique codes used for such purposes include linear or 2-dimensional barcodes, human- readable combinations of letters / numbers or unique serialized codes that can be written onto an RFID tag or label.

Packaging 52

Packaging Packaging Production Manufacturing 52

pharmaphorum

JANUARY 5, 2021

Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Immune Response 52

Immune Response FDA Approval Drugs Sales 52

pharmaphorum

APRIL 5, 2022

The one-year survival rate with the drug was 73%, compared to 58% in a group receiving standard-of-care – off-label immune checkpoint inhibitors used for other forms of melanoma like Merck & Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Yervoy (ipilimumab) or chemotherapy with dacarbazine.

Protein 52

Protein Sales Drugs Trials 52

XTalks

JANUARY 28, 2022

Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose. The study evaluated the effectiveness of Kimmtrak against two immune checkpoint inhibitors (Merck’s Keytruda and Bristol Myers Squibb’s Yerboy) and the chemotherapy dacarbazine (as per clinician choice) used as conventional treatments for the disease.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

pharmaphorum

OCTOBER 29, 2021

Merck is the obvious partner for that ambition as Keytruda is in the ascendency among checkpoint inhibitors for TNBC, having also recently also picked up an FDA approval pre-surgery alongside chemotherapy in the neoadjuvant setting, as well as in the post-surgery (adjuvant) setting as a monotherapy, to prevent tumours from recurring.

Trials 52

Trials Sales FDA Approval Production 52